S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CMPX · Compass Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Compass Therapeutics Inc. (CMPX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.82
-0.02
(-2.67%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.82
$0.81
$0.84
52-WEEK RANGE
$0.82
$0.82
$6.88
What's happening
- CMPX is down 2.67% today, trading at $0.82. — Live quote
- It's trading within 3% of its 52-week low ($0.82). (Finnhub fundamentals)
- Volume today (50,985) is well below its 3-month average of 3,950,790. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.13 actual vs. $-0.11 estimated (-17.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 9
Hold 4
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (21 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CMPX
-84.48%
vs S&P 500
-97.26%
1-YEAR RETURN
CMPX
-79.42%
vs S&P 500
-93.99%
6-MONTH RETURN
CMPX
-87.24%
3-MONTH RETURN
CMPX
-60.32%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.13
Est. $-0.11
MISS -17.6%
2026-04-26 (Q1 2026)
$-0.10
Est. $-0.10
BEAT +0.1%
2026-01-26 (Q4 2025)
$-0.09
Est. $-0.09
BEAT +2.4%
2025-10-26 (Q3 2025)
$-0.08
Est. $-0.14
BEAT +43.0%
Valuation Measures & Ratios
Enterprise Value4$111.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)172.57
Price / Book72.38
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-29.94%
Return on Assets (ROA9)-26.35%
Avg Volume (3M)3,950,790
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short40,357,710
Change from Prior Settlement-3.10%
% of Float—
Days to Cover (Short Ratio)6.26
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -79.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CMPX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$27.0M | -$20.3M | -$15.8M | -$21.1M | -$18.0M | -$12.2M | -$15.0M | -$12.8M |
| Net income | -$25.2M | -$18.3M | -$14.3M | -$19.9M | -$16.6M | -$10.5M | -$13.1M | -$10.8M |
| EPS (basic) | $-0.13 | $-0.10 | $-0.08 | $-0.14 | $-0.12 | $-0.08 | $-0.10 | $-0.08 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $190.2M | $205.2M | $219.6M | $231.3M | $116.7M | $131.5M | $140.4M | $149.2M |
| Total liabilities | $24.1M | $18.7M | $22.8M | $21.6M | $23.5M | $21.2M | $15.2M | $10.8M |
| Stockholders' equity | $166.0M | $186.5M | $196.8M | $209.6M | $93.2M | $110.3M | $125.2M | $138.4M |
| Total current assets | $180.9M | $195.7M | $209.8M | $221.1M | $106.2M | $124.1M | $132.8M | $141.1M |
| Total current liabilities | $16.1M | $10.3M | $14.0M | $12.4M | $13.9M | $14.9M | $8.9M | $4.4M |
| Cash & equivalents | $35.5M | $55.2M | $30.6M | $46.2M | $22.9M | $41.0M | $43.5M | $19.4M |
| Marketable securities (current) | $144.4M | $139.5M | $178.3M | $173.7M | $78.1M | $71.6M | $83.2M | $98.6M |
| Property, plant & equipment | $324.0K | $169.0K | $102.0K | $119.0K | $131.0K | $102.0K | $353.0K | $493.0K |
| Other non-current assets | — | — | — | — | — | — | $568.0K | $568.0K |
| Accounts payable | $2.9M | $906.0K | $1.6M | $3.1M | $2.6M | $1.6M | $2.2M | $960.0K |
| Accrued liabilities | $11.6M | $8.0M | $11.4M | $8.7M | $11.0M | $13.2M | $6.3M | $2.9M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $18.0K | $18.0K | $18.0K | $53.0K | $14.0K | $14.0K | $14.0K | $14.0K |
| Retained earnings | -$474.6M | -$449.5M | -$431.2M | -$415.5M | -$401.2M | -$381.3M | -$364.7M | -$349.7M |
| Accumulated other comprehensive income (loss) | -$251.0K | -$159.0K | $280.0K | $274.0K | $208.0K | $190.0K | $210.0K | $486.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.7M | -$17.3M | -$13.3M | -$10.8M | -$11.8M | -$13.2M | -$9.2M | -$11.1M |
| Investing cash flow | -$5.0M | $38.4M | -$3.4M | -$95.2M | -$6.4M | $11.6M | $15.4M | $29.0M |
| Financing cash flow | $0 | $3.4M | $1.1M | $129.4M | $0 | -$815.0K | -$94.0K | -$2.0K |
| Free cash flow | -$14.9M | -$17.4M | -$13.3M | -$10.9M | -$11.8M | -$13.2M | -$9.2M | -$11.1M |
| Capital expenditures | $176.0K | $82.0K | $0 | $7.0K | $0 | $18.0K | $0 | $44.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $4.8M | $5.1M | $1.8M | $1.2M | $2.8M | $2.5M | $2.2M | $2.2M |
| Change in accounts payable | $2.0M | -$679.0K | -$1.5M | $500.0K | $1.0M | -$672.0K | $1.3M | -$232.0K |
| Purchases of investments | $40.6M | $44.8M | $27.5M | $109.1M | $33.2M | $24.8M | $9.9M | $5.3M |
| Tax withholding on stock comp | $0 | $489.0K | $212.0K | $0 | $0 | $815.0K | $96.0K | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M |
| EPS (basic) | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M |
| Stockholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M |
| Total current assets | $209.8M | $132.8M | $153.9M | $194.8M | $147.1M |
| Total current liabilities | $14.0M | $8.9M | $7.8M | $16.2M | $10.6M |
| Cash & equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M |
| Marketable securities (current) | $178.3M | $83.2M | $128.2M | $151.7M | $0 |
| Property, plant & equipment | $102.0K | $353.0K | $898.0K | $1.6M | $2.2M |
| Other non-current assets | — | $568.0K | $320.0K | $320.0K | $320.0K |
| Accounts payable | $1.6M | $2.2M | $4.1M | $3.4M | $867.0K |
| Accrued liabilities | $11.4M | $6.3M | $2.5M | $11.7M | $8.8M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | — | — | — | — | $0 |
| Common stock & paid-in capital | $18.0K | $14.0K | $13.0K | $13.0K | $10.0K |
| Retained earnings | -$431.2M | -$364.7M | -$315.3M | -$272.8M | -$233.6M |
| Accumulated other comprehensive income (loss) | $280.0K | $210.0K | $37.0K | -$302.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Investing cash flow | -$93.3M | $46.8M | $27.0M | -$151.2M | -$1.8M |
| Financing cash flow | $129.6M | $17.3M | $2.9M | $75.8M | $118.6M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Capital expenditures | $25.0K | $44.0K | $30.0K | $212.0K | $1.6M |
| Depreciation & amortization | — | — | — | — | $600.0K |
| Share-based compensation | $8.4M | $8.6M | $6.1M | $5.3M | $4.0M |
| Change in accounts payable | -$664.0K | -$1.8M | $708.0K | $2.5M | -$194.0K |
| Purchases of investments | $194.6M | $88.2M | $155.4M | $200.1M | $0 |
| Tax withholding on stock comp | $1.0M | $232.0K | $159.0K | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CMPX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-04-07 to 2026-10-01
Recent transactions
- Insiders have net bought 22,500 shares over the last 182 days, across 2 purchases and 0 sales.
- Most recent: Lerner Neil (Chief Accounting Officer) — Open market purchase of 20,000 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)22,500 sh(2 txns)
Sales (open market)0 sh(0 txns)
Net Shares+22,500
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer | Open market purchase | 2026-10-01 | 20,000 |
| Anderman Jonathan | General Counsel | Grant / award | 2026-04-29 | 25,000 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Tax withholding | 2026-02-08 | 36,687 |
| Shin Barry | CFO | Grant / award | 2026-01-02 | 125,000 |
| GORDON CARL L | Director | Open market sale | 2025-04-09 | 3,571,428 |
| ORBIMED ADVISORS LLC | Director | Open market sale | 2025-04-09 | 3,571,428 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Lerner Neil | Chief Accounting Officer | Open market purchase | 20,000 | $0.92 |
| 2026-09-24 | Lerner Neil | Chief Accounting Officer | Open market purchase | 2,500 | $1.14 |
| 2026-04-29 | Anderman Jonathan | General Counsel | Grant / award | 25,000 | $1.89 |
| 2026-04-29 | Lerner Neil | Chief Accounting Officer | Grant / award | 15,000 | $1.89 |
| 2026-02-08 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Tax withholding | 36,687 | $6.52 |
| 2026-01-09 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Tax withholding | 46,777 | $5.35 |
| 2026-01-02 | Shin Barry | CFO | Grant / award | 125,000 | $5.17 |
| 2026-01-02 | Schuetz Thomas J. | CEO | Grant / award | 250,000 | $5.17 |
| 2026-01-02 | Lerner Neil | Chief Accounting Officer | Grant / award | 62,500 | $5.17 |
| 2026-01-02 | Anderman Jonathan | General Counsel | Grant / award | 150,000 | $5.17 |
| 2025-11-16 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Tax withholding | 44,025 | $4.83 |
| 2025-05-27 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Open market purchase | 10,000 | $2.11 |
| 2025-04-09 | GORDON CARL L | Director | Open market sale | 3,571,428 | $1.59 |
| 2025-04-09 | ORBIMED ADVISORS LLC | Director | Open market sale | 3,571,428 | $1.59 |
| 2025-04-07 | Anderman Jonathan | Gen Counsel & Corporate Sec | Open market purchase | 20,000 | $1.54 |
| 2025-04-07 | Lerner Neil | CHIEF ACCOUNTING OFFICER | Open market purchase | 20,000 | $1.42 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-07-01 | View on SEC.gov → |
| 2026-06-23 | 8-K | 2026-06-22 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-05-05 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-05 | 8-K | 2026-05-05 | View on SEC.gov → |
| 2026-04-29 | 4 | 2026-04-29 | View on SEC.gov → |
| 2026-04-29 | 4 | 2026-04-29 | View on SEC.gov → |
Recent news
Headlines about CMPX (Compass Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Australian ETF Movers for Tuesday | Betashares Crd Oil Idx Ccy Hdg Cmpx ETF Was the Top Gainer
Moomoo · 2026-10-20 -
Compass Therapeutics, Inc. (CMPX) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
Compass Therapeutics Stock Price Forecast. Should You Buy CMPX?
StockInvest.us · 2026-10-16 -
Emergent BioSolutions stock falls as CFO plans retirement
Yahoo · 2026-10-16 -
CMPX Dec 2026 9.000 call (CMPX261218C00009000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-16 -
CMPX261016C00004000 Interactive Stock Chart | CMPX Oct 2026 4.000 call Stock
Yahoo Finance · 2026-10-15 -
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo · 2026-10-14 -
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns
Yahoo · 2026-10-14
No headlines in this category right now — try “All”.